RAD51 and chronic myelogenous leukemia, BCR-ABL1 positive: On the other hand, CML cells appear to be sensitive to the combination of IM and DNA damaging treatments such as inhibition of NEDD8 activating enzyme (NAE1) [68] and Rad51 [69].